The US Food and Drug Administration (FDA) has approved KRAZATI, a targeted treatment for adult patients with KRAS metastatic non-small cell lung cancer (NSCLC), developed by Mirati Therapeutics Inc. Based on the objective response rate (ORR) and duration of response (DOR), the treatment receives expedited approval. The description and verification of a clinical benefit in […]
Continue Reading
Merck, which is known as MSD outside of Canada and the United States has announced that, the US FDA has approved for reviewing a new supplemental Biologics Licence Application (sBLA) seeking a new review for the Keytruda for the treatment of the patients with the non-small cell lung cancer followed by the complete surgical resection. […]
Continue Reading
CorePath Laboratories is excited for announcing a partnership with Cizzle Biotechnology, a diagnostic developer based in the United Kingdom for the purpose of developing and offering a priority in the early-stage lung cancer test throughout the United States of America. Lung Cancer has been the main cause of cancer deaths in the United States of […]
Continue Reading